Research & Resources
Information about pipeline products or their investigational uses neither implies FDA approval nor confirms their safety or efficacy. Additionally, FDA approval for these products or potential uses is not guaranteed.
Publications
Long-Term Results From an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy
Journal of the American Society of Nephrology
Barratt J, et al.
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Atacicept for Treatment of IgA Nephropathy
Kidney International
Lafayette R, et al.
The Role of BAFF and APRIL in IgA Nephropathy: Pathogenic Mechanisms and Targeted Therapies
Frontiers in Nephrology
Cheung CK, et al.
Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria
Kidney International Reports
Barratt J, et al.
New Strategies and Perspectives on Managing IgA Nephropathy
Clinical and Experimental Nephrology
Selvaskandan H, et al.
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
Clinical Journal of the American Society of Nephrology
Thompson A, et al.
IgA Nephropathy
New England Journal of Medicine
Wyatt R, et al.
An Update on the Pathogenesis and Treatment of IgA Nephropathy
Kidney International
Boyd J, et al.
The Level of Galactose-Deficient IgA1 in the Sera of Patients With IgA Nephropathy Is Associated With Disease Progression
Kidney International
Zhao N, et al.
Patients With IgA Nephropathy Have Increased Serum Galactose-Deficient IgA1 Levels
International Society of Nephrology
Moldoveanu Z, et al.
Continuing Medical Education
Examining B-Cell Immunomodulation as Treatment for IgAN
Medlive
Therapeutic Advances in IgAN: Harnessing the Potential of B-Cell Modulation
PeerVoice
How Does the B-Cell Pathway Influence IgA Nephropathy?
Medscape
Digging Deep Into the Data for Emerging Treatments Targeting the B Cell Pathway in IgAN
Medscape
Additional Medical Education
Targeting the Source of IgA Nephropathy: Focus on B-Cell Modulation
Presented by: Dr. Dana Rizk, Dr. Shikha Wadhwani, and Dr. Richard Lafayette
ERA 2025
Targeting the Source of IgA Nephropathy: Focus on BAFF and APRIL Pathways
Presented by: Dr. Vivekanand Jha, Dr. Suceena Alexander, and Dr. Jonathan Barratt
WCN 2025
Targeting the Source of IgA Nephropathy: Focus on BAFF and APRIL Pathways
Presented by: Dr. Chee Kay Cheung, Dr. Heather Reich, and Dr. Jürgen Floege
ERA 2024